Alivus Life Sciences Limited has announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for ₹9.12 crore. The transaction marks a strategic expansion into formulation development, leveraging the target’s expertise in oral solids, sterile injectables, and ophthalmic solutions for regulated markets including the US, EU, and Latin America.

Acquisition details

The key parameters of the board-approved transaction are outlined below:

The acquisition enables Alivus to extend its operational footprint beyond its core Active Pharmaceutical Ingredients (APIs) business. By integrating IQGenX’s platform, Alivus aims to create an end-to-end service model that includes pre-formulation studies, prototype development, process optimisation, and regulatory submission support.

Strategic rationale

While APIs anchor Alivus’s existing operations, this move allows the company to leverage its portfolio selectively into advanced formulation development. The combined entity will offer deep scientific expertise across complex delivery formats, supported by rigorous bioequivalence and stability studies.

Key strategic objectives include:

• Expanding the global customer base in the generic pharmaceutical segment.
• Scaling value propositions for Contract Development and Manufacturing Organisation (CDMO) customers through seamless scale-up and clinical supplies.
• Curating a high-impact basket of differentiated, niche assets, primarily in Oncology, for strategic out-licensing.

IQGenX Pharma, founded in October 2016, operates as a custom research organization specializing in formulation development for highly regulated markets. Alivus plans to utilise IQGenX’s specialised platform alongside its own world-class API portfolio to enhance its competitive positioning.

Financial profile of target

IQGenX Pharma Private Limited is registered at Navi Mumbai, Maharashtra. The company reported a turnover of ₹348.0 lakh for the financial year ended March 31, 2026 (FY26). This represents growth from ₹318.2 lakh in FY25 and ₹267.5 lakh in FY24.

Closing timeline

The acquisition is subject to customary closing condition precedents. The company expects the transaction to close by December 6, 2026, or such date as may be agreed upon from the execution of the Share Purchase Agreement (SPA).

The SPA stipulates that if the conditions precedent are not met within the specified timeline, the sellers will enter into a Business Transfer Agreement with Alivus, whereby the entire business, including employees and assets, will be acquired by the company.

Alivus Life Sciences has scheduled a series of one-on-one investor and analyst meetings for August 18 and 19, 2026. The company disclosed the schedule under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These engagements aim to facilitate direct interaction between the management and key market participants.

The meetings will be conducted in both in-person and virtual formats. Most sessions are scheduled to take place in Mumbai, with one session held virtually. The company noted that the schedule and mode of meetings may change due to exigencies on the part of the investors, analysts, or the company.

Meeting Schedule

The detailed schedule of the investor interactions is as follows:

Regulatory Disclosure

Alivus Life Sciences Limited submitted the intimation to the Bombay Stock Exchange and the National Stock Exchange of India. The disclosure was signed by Rudalf Corriea, the Company Secretary and Compliance Officer, on August 13, 2026. The filing references scrip code 543322 for Alivus on the BSE.